Key Findings
- A 2016 meta-analysis (Chiu et al., 789 participants) found oral magnesium was associated with reduced migraine attack frequency and intensity (odds ratios 0.20 and 0.27).
- A 2019 meta-analysis (Okoli et al., 226 participants across 3 trials) found NO statistically significant effect of magnesium on migraine outcomes and judged the evidence insufficient.
- A 2025 dose-response meta-analysis (Talandashti et al.) reported magnesium was associated with fewer migraine attacks (mean difference −2.51).
- Overall the evidence is mixed and trial quality varies; magnesium's low cost and good safety profile are part of why it is still considered.